Aerobic Exercise & Resistant Hypertension

Status Recruiting

Clinical Trial Summary

This study will examine the effects of 4 months of aerobic interval training versus continuous aerobic training on ambulatory blood pressure (ABP) and novel plasma protein biomarkers in patients with resistant hypertension. In addition, we will measure ABP after a training cessation period of 3 months (i.e., 7 months follow-up). A randomized controlled trial will be performed including two exercise groups and a control group: a) moderate-intensity interval training (MIIT); b) moderate-intensity continuous training (MICT); c) usual care. MIIT could represent a superior training modality that exceeds the benefits of MICT in patients with resistant hypertension.

Clinical Trial Description

Hypertension is associated with an increased risk of cardiovascular morbidity and mortality, and its high prevalence remains a worldwide concern. Ambulatory blood pressure monitoring (ABPM) is recognized in the diagnosis and management of hypertension, and can control blood pressure better than clinic assessment. Different studies have examined the effects of aerobic training on ABP in patients with hypertension, but the effects of moderate-intensity interval training (MIIT) and moderate-intensity continuous training (MICT) on ABP and novel plasma protein biomarkers that could potentially serve to identify cardiovascular risk, have not yet been examined in patients with resistant hypertension.To fill this gap, our aims are to determine the effects of MIIT and MICT for 4 months on ABP (primary endpoint), and on proteomic biomarkers (secondary endpoints) in patients with resistant hypertension. In addition, we will measure ABP after a training cessation period of 3 months (i.e., 7 months follow-up). A total of 72 participants will be randomly divided into three groups: the first group (n=24) will perform MIIT, the second group (n=24) will perform MICT, and the third control group (n=24) will maintain usual care for 4 months. All will receive usual care for 7 months, with the structured physical exercise as the only relevant change in the intervention groups. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05563077
Study type	Interventional
Source	Universidad Europea de Madrid
Contact	Roberto Gómez Valea
Phone	+34917407272
Email	roberto.gomez@universidadeuropea.es
Status	Recruiting
Phase	N/A
Start date	October 5, 2022
Completion date	August 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05545059` - Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension	Phase 3
Not yet recruiting	`NCT04388124` - VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION	Phase 2
Withdrawn	`NCT01939392` - Rapid Renal Sympathetic Denervation for Resistant Hypertension II	Phase 2/Phase 3
Recruiting	`NCT06228677` - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting	`NCT04213963` - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Recruiting	`NCT03758196` - Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension（RSDARH）	N/A
Active, not recruiting	`NCT03179800` - CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™	N/A
Completed	`NCT04519658` - A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)	Phase 2
Not yet recruiting	`NCT05552300` - Superselective Adrenal Arterial Embolization for Resistant Hypertension	N/A
Not yet recruiting	`NCT05426707` - Remote Ischemic Conditioning for the Treatment of Resistant Hypertension	N/A
Completed	`NCT04345198` - Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension	N/A
Active, not recruiting	`NCT05562934` - An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.	Phase 2
Recruiting	`NCT06034743` - A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension	Phase 3
Withdrawn	`NCT02926495` - Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.	N/A
Active, not recruiting	`NCT02670681` - Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects	N/A
Completed	`NCT02572024` - The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study)	N/A
Terminated	`NCT02295683` - Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
Completed	`NCT02001350` - Carotid Ultrasound Study	N/A
Recruiting	`NCT04331691` - Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension	Phase 4
Recruiting	`NCT04637152` - Sacubitril/Valsartan in Resistant Hypertension	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Aerobic Exercise and Resistant Hypertension

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms